about
Phase 1 Trials of rVSV Ebola Vaccine in Africa and EuropeClindamycin as an antimalarial drug: review of clinical trials.A phase 3 trial of RTS,S/AS01 malaria vaccine in African infantsInduction of Plasmodium falciparum-specific CD4+ T cells and memory B cells in Gabonese children vaccinated with RTS,S/AS01(E) and RTS,S/AS02(D)Molecular characterization of Shigella spp. from patients in Gabon 2011-2013.The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient dataImmunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trialFull blood count and haemozoin-containing leukocytes in children with malaria: diagnostic value and association with disease severityA randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon.Does treatment of intestinal helminth infections influence malaria? Background and methodology of a longitudinal study of clinical, parasitological and immunological parameters in Nangapanda, Flores, Indonesia (ImmunoSPIN Study)Phylogenetic nomenclature and evolution of mannose-binding lectin (MBL2) haplotypes.Impact of short-time urine freezing on the sensitivity of an established Schistosoma real-time PCR assay.A longitudinal study of allergy and intestinal helminth infections in semi urban and rural areas of Flores, Indonesia (ImmunoSPIN Study).Assessment of the effect of Schistosoma haematobium co infection on malaria parasites and immune responses in rural populations in Gabon: study protocol.Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine.In-vitro characterization of novel and functional regulatory SNPs in the promoter region of IL2 and IL2R alpha in a Gabonese populationThe effect of three-monthly albendazole treatment on malarial parasitemia and allergy: a household-based cluster-randomized, double-blind, placebo-controlled trial.Short-course artesunate treatment of uncomplicated Plasmodium falciparum malaria in Gabon.Fosmidomycin, a novel chemotherapeutic agent for malaria.Clinical, environmental, and serologic surveillance studies of melioidosis in Gabon, 2012-2013High prevalence of dhfr triple mutant and correlation with high rates of sulphadoxine-pyrimethamine treatment failures in vivo in Gabonese childrenThe effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infantsIncidence, pathogens and resistance patterns of nosocomial infections at a rural hospital in Gabon.Pentoxifylline as an adjunct therapy in children with cerebral malaria.A thirteen-year analysis of Plasmodium falciparum populations reveals high conservation of the mutant pfcrt haplotype despite the withdrawal of chloroquine from national treatment guidelines in Gabon.Cost-effectiveness of intermittent preventive treatment of malaria in infants (IPTi) for averting anaemia in Gabon: a comparison between intention to treat and according to protocol analyses.Effect of Antihelminthic Treatment on Vaccine Immunogenicity to a Seasonal Influenza Vaccine in Primary School Children in Gabon: A Randomized Placebo-Controlled Trial.Artesunate--amodiaquine combination therapy for falciparum malaria in young Gabonese children.Randomized controlled trial of fosmidomycin-clindamycin versus sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malariaThe use of paediatric artemisinin combinations in sub-Saharan Africa: a snapshot questionnaire survey of health care personnel.Pharmacokinetics of ferroquine, a novel 4-aminoquinoline, in asymptomatic carriers of Plasmodium falciparum infections.A pilot study on cytotoxic T lymphocyte-4 gene polymorphisms in urinary schistosomiasisWillingness to Know the Cause of Death and Hypothetical Acceptability of the Minimally Invasive Autopsy in Six Diverse African and Asian Settings: A Mixed Methods Socio-Behavioural Study.Socio-economic status is inversely related to bed net use in Gabon.Antipyretic effect of ibuprofen in Gabonese children with uncomplicated falciparum malaria: a randomized, double-blind, placebo-controlled trial.Therapeutic and prophylactic effect of intermittent preventive anti-malarial treatment in infants (IPTi) from Ghana and Gabon.Opposed circulating plasma levels of endothelin-1 and C-type natriuretic peptide in children with Plasmodium falciparum malaria.Haplotype specific-sequencing reveals MBL2 association with asymptomatic Plasmodium falciparum infection.Malaria in pregnancy in rural Gabon: a cross-sectional survey on the impact of seasonality in high-risk groups.
P50
Q24289281-CFFB289F-3356-4057-9001-E5BF37F05148Q24536057-D2C875AC-D11B-4D06-A4F2-3A9356063EE7Q28278852-EDA4F72D-AA74-4C2A-9134-5B91CBC393F1Q28741242-2B56638C-B1CC-46DE-AB31-4617A395437AQ30368857-30A370F4-3865-4D78-9BEB-D7DC6E497A0CQ30936416-488E6F3A-A959-4FED-9BF9-BEFC1017FCC3Q30991737-2A863B62-673B-43E5-8BED-4CBD162F3794Q33343300-20BF10C6-C2A3-4596-A10C-183C8DA64AEDQ33512921-A0B8DBD0-D736-4187-A23F-1D53E16A00CBQ33546171-EB9DAAEF-F17E-4CAB-84D4-BC9C71DDA45EQ33577516-E880748E-FA35-47B6-AEA7-A406FD4DCB02Q33719640-B90F7291-67EC-4027-9DAF-521276CBBF7EQ33860428-6D268911-834C-42E3-BFB2-E0560922AA9AQ34028797-E9E38AA6-F1D5-414B-A80A-B43E35D79BE2Q34202910-8E9DD29A-95A3-49D5-9AE2-F999662D9F1EQ34487139-6B68F74E-1ACE-4CAC-8C19-855C68546E58Q34502867-058F7C89-151C-4994-BA2A-F863E65CC2A0Q34634037-553D5B23-D504-4CA3-B6F8-ADA84C82D197Q34734703-D01C5DAE-76FE-4B42-AED6-BCD97BD6FC1AQ34823125-028C6DEB-F53A-4906-A380-EF6C5795CE12Q34843970-F7C73BDE-E089-428A-BDC7-CDCF15F67DDCQ35038632-ABABE070-DD27-425C-8290-42662E9ECF20Q35105075-4095CEC1-5E77-4C3D-B725-2E3842184A86Q35110059-070F00C6-2A2A-4D0B-85A4-64A060828A53Q35154563-8D7676D8-7627-482F-B70D-A7736E767529Q35549781-AA2FC56A-40E9-4F87-938E-6E29CC5F56D4Q35573781-F2C77406-3C91-49B9-AE4B-47BA6AAB50B8Q35656728-A203DE2C-F601-4FDA-B034-7D3167128CC4Q35695222-84A6BBC9-C19E-4F46-9C5B-B6E8FBA6CF94Q35759028-C09CF645-F2D7-4D56-9B3E-EF41D0E6CC8EQ35761615-A52B53B0-E0DB-41BD-8517-C35D94271F08Q36018719-5173FA1F-0AE0-4652-A6B3-91323FC76448Q36117526-34576CDF-7607-48F5-862D-2533E073C270Q36201016-37AC41A0-81ED-4B8B-8BB5-13FCE7BD5ABDQ36606694-0F22ABE7-CED2-413C-9763-FDB686097AB6Q36693763-97EC0DA4-4AC8-40CE-8886-D483C8263F5BQ36981978-E3115255-D2D5-4D96-A099-9B4E6B6D38B8Q37071264-6FBAC5F4-7413-409E-AB72-255112E5BDFDQ37209510-3657A5CC-6CD2-4334-B2AA-AD1574E17786Q37315138-ED410F3F-6FA6-48B4-BDFA-FE2F95A1BB03
P50
description
researcher ORCID ID = 0000-0003-1427-3002
@en
wetenschapper
@nl
name
Bertrand Lell
@ast
Bertrand Lell
@en
Bertrand Lell
@es
Bertrand Lell
@nl
type
label
Bertrand Lell
@ast
Bertrand Lell
@en
Bertrand Lell
@es
Bertrand Lell
@nl
prefLabel
Bertrand Lell
@ast
Bertrand Lell
@en
Bertrand Lell
@es
Bertrand Lell
@nl
P21
P31
P496
0000-0003-1427-3002